Page 280 - Read Online

Finzel et al. J Cancer Metastasis Treat 2018;4:21 I http://dx.doi.org/10.20517/2394-4722.2018.10 Page 9 of 10

which cannot be achieved by performing only one type of biopsy, and that the inclusion of ctDNA profiling
should be considered in routine oncology care especially for cancers where targeted therapies are approved
or in development.

DECLARATIONS
Acknowledgments
We thank all the clinicians and patients who provided the biopsy samples used in the study.

Authors’ contributions
Conceived and designed the study: Laes JF
Worked on the acquisition of data, the writing of the article and the analysis and interpretation of data: all
authors
Reviewed and agreed on the manuscript before submission: all authors

Data source and availability
Due to privacy reasons, the data of this study cannot be open for readers. Nonetheless, if a researcher asks
for data, they could be shared upon the signature of a confidentiality agreement.

Financial support and sponsorship
This study was sponsored by OncoDNA SA. The costs associated with the development and publishing of the
manuscript were provided by OncoDNA SA.

Conflicts of interest
All authors are employees of OncoDNA. Ghitti G and Laes JF report ownership of OncoDNA shares.

Patient consent
Patients gave informed consent for their tumor analysis data to be published.

Ethics approval
This study is not approved by IRB; however, all patients signed an informed consent before their samples
underwent molecular profiling according to Belgian law.

Copyright
© The Author(s) 2018.

REFERENCES
1. La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol
2011;8:587-96.
2. Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer 2015;137:262-6.
3. Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Front Pharmacol 2013;4:1-8.
4. Seoane J, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. J Intern Med 2014;276:41-51.
5. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501:346-54.
6. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012;13:e178-85.
7. Yi X, Ma J, Guan Y, Chen R, Yang L, Xia X. The feasibility of using mutation detection in ctDNA to assess tumor dynamics. Int J
Cancer 2017;140:2642-7.
8. Diaz LJ, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
9. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of
age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017;17:223-38.
10. Clatot F, Augusto L, Di Fiore F. ESR1 mutations in breast cancer. Aging (Albany NY) 2017;9:3-4.
11. Bronte G, Silvestris N, Castiglia M, Galvano A, Passiglia F, Sortino G, Cicero G, Rolfo C, Peeters M, Bazan V, Fanale D, Giordano A,